Standout Papers
Citation Impact
Citing Papers
Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course
2008
Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape
2011
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
2010
Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma
2011
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
2010
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
2010
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
2010
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
2010
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
2010
Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities
2006
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
2006
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
2002
Hallmarks of Cancer: The Next Generation
2011 Standout
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
2012
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma
2004
Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
2013
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
2007
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma
2009
Primary Central Nervous System Lymphoma: From Clinical Presentation to Diagnosis
1999
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents
2007
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
2012
Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
2007
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
2008
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
2010
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
2006 Standout
Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas
2012
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
2016
Genetic Pathways to Primary and Secondary Glioblastoma
2007
Advances in Radiation Therapy for Brain Tumors
2007
The status of gene therapy for brain tumors
2007
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
2006 Standout
NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report
2005
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
2010
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
2011
The clinical value of proton magnetic resonance spectroscopy in adult brain tumours
2007
Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents
2000 Standout
Glioblastoma and Other Malignant Gliomas
2013 Standout
Adjuvant combined modality therapy for malignant meningiomas
1996
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
2005
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Thromboembolic disease in patients with high-grade glioma
2012
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
2012
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
2008
Metabolism and action of amino acid analog anti-cancer agents
1990
Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury
2005
Radiotherapy for Glioblastoma in the Elderly
2007
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
2012
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review
2011
Facets and determinants of quality of life in patients with recurrent high grade glioma
2005
A phase 3 trial of local chemotherapy with biodegradable carmustine(BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
2003 Standout
Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance
2005
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
2008
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers
2008 Standout
Anatomic, Physiologic and Metabolic Imaging in Neuro-Oncology
2008
Antiangiogenic therapy in malignant gliomas
2008
Survival of human glioma cells treated with various combination of temozolomide and X-rays
2000
Inhibition of angiogenesis and invasion in malignant gliomas
2007
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
2015
Antibodies in oncology
2011
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma
2005
EXTENT OF SURGICAL RESECTION IS INDEPENDENTLY ASSOCIATED WITH SURVIVAL IN PATIENTS WITH HEMISPHERIC INFILTRATING LOW-GRADE GLIOMAS
2008
Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen
2013
Molecularly targeted therapy for malignant glioma
2007
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Advances in Brain Tumor Surgery
2007
Psychosocial and supportive-care needs in high-grade glioma
2008
Antibody therapy of cancer
2012 Standout
Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas
2005
Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis
1999
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas
2003
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol
2004
A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma
1999
Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome
2001
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
2012
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
2009
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
2010
Gliomagenesis: genetic alterations and mouse models
2001
Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague
2010 StandoutNobel
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
2005
Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication
2006
The Role of Surgery in Low Grade Gliomas
1999
Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients
1996
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
2010
Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression
2023
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
2008
BRACHYTHERAPY FOR BRAIN TUMOR
1999
Epidemiology of Brain Tumors
2007
Anaplastic Oligodendroglioma and Oligoastrocytoma
2007
Advanced MRI of Adult Brain Tumors
2007
Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods1
2006
Quantitative imaging biomarkers in neuro-oncology
2009
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
2001
A comprehensive outlook on intracerebral therapy of malignant gliomas
2010
Unraveling the therapeutic potential of the Hedgehog pathway in cancer
2013 Standout
Salvage Chemotherapy with CPT-11 for Recurrent Glioblastoma Multiforme
2002
Medical management of patients with brain tumors
2006
Malignant Gliomas in Adults
2008 Standout
Angiogenesis in brain tumours
2007
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
2016
DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response
1996
Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial
2006
Validation and Predictive Power of Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis Classes for Malignant Glioma Patients: A Report Using RTOG 90-06☆
1998
Delayed repletion of O6-methylguanine—DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity
2003
Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme
2006
Inhibiting kinases in malignant gliomas
2007
Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance
2004
Fluorescence-guided surgery with live molecular navigation — a new cutting edge
2013 Nobel
Current and future developments in the use of temozolomide for the treatment of brain tumours
2001
Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
2009
Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas1
2006
Response criteria for glioma
2008
Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life
2010
Glioma Stem Cells: A Midterm Exam
2008
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
1998
Primary brain tumours in adults
2003
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors
1999
IMPACT OF INTRAOPERATIVE HIGH-FIELD MAGNETIC RESONANCE IMAGING GUIDANCE ON GLIOMA SURGERY
2009
Primary brain tumours in adults
2012 Standout
Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling
2017 StandoutNatureNobel
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
2011
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
2001 Standout
Antiangiogenic therapies for high-grade glioma
2009
Comparison of a Strategy Favoring Early Surgical Resection vs a Strategy Favoring Watchful Waiting in Low-Grade Gliomas
2012
Role of Radiation Therapy and Radiosurgery in Glioblastoma Multiforme
2003
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
2006
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
Identification of human brain tumour initiating cells
2004 StandoutNature
Rituximab: Mechanism of Action
2010
Extent of Resection as a Prognostic Variable in the Treatment of Gliomas
1999
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
2006
Cancer-related inflammation
2008 StandoutNature
Brain Tumor Imaging in Clinical Trials
2008
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion
2011
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures
2012
High-dose methotrexate for elderly patients with primary CNS lymphoma
2008
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010
Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred?
2010
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up
2009
Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas
1999
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
2001 Standout
Diagnosis and Treatment of High-Grade Astrocytoma
2007
Novel anti-angiogenic therapies for malignant gliomas
2008
Brain Tumors
2001 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
2008
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Cellular senescence: from physiology to pathology
2014 Standout
Identification of Novel Tumor-Associated Cell Surface Sialoglycoproteins in Human Glioblastoma Tumors Using Quantitative Proteomics
2014
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme
2000
Primary lymphoma of the central nervous system: just DLBCL or not?
2008
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.
1997 StandoutNobel
Human Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
2005
The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine
2002
Primary CNS Lymphoma in Immunocompetent Patients
2009
Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia
2001
Multifaceted end points in brain tumor clinical trials: Cognitivedeterioration precedes MRI progression
2003
Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma
2007
Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles
1999 Standout
Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
2008 StandoutNobel
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
Update on brain tumor imaging: from anatomy to physiology.
2006
Efficacy of Fractionated Stereotactic Reirradiation in Recurrent Gliomas: Long-Term Results in 172 Patients Treated in a Single Institution
2005
Bevacizumab and chemotherapy for recurrent glioblastoma
2009
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
2008
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 Standout
Molecular Predictors in Glioblastoma
2008
Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
2005
Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors
2008
Recent Advances on Surface Engineering of Magnetic Iron Oxide Nanoparticles and Their Biomedical Applications
2007
Angiogenesis as a Therapeutic Target in Malignant Gliomas
2009
Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications
2008 Standout
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
2003
Diagnosis and Treatment of Recurrent High-Grade Astrocytoma
2006
Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide
2004
Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities
2003
Therapeutic Targeting of the Tumor Microenvironment
2021
Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A
2011 StandoutNobel
The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2
1997 Standout
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
2005
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
2011
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
2009
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents
2003
EGFR Activation Results in Enhanced Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase–Dependent Activation of the Sp1/Sp3 Transcription Factors in Human Gliomas
2007
Insights into Cytokine–Receptor Interactions from Cytokine Engineering
2014
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
2009
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
2007
Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers
2007
Low grade glioma: a measuring radiographic response to radiotherapy.
1999
Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial
2006
Long-term outcome of low-grade oligodendroglioma and mixed glioma
2000
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
2008
Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394
2003
Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results
2005
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
2008 Standout
CT and MR imaging after placement of the GliaSite radiation therapy system to treat brain tumor: initial experience.
2004
Exploiting Exosomes in Cancer Liquid Biopsies and Drug Delivery
2019
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.
2001
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
2007
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
2008
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
2007
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
2004
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme
2005
Cancer Genome Landscapes
2013 StandoutScience
Phase II Trial of Gefitinib in Recurrent Glioblastoma
2003
Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma.
2002 StandoutNobel
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas
2003
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
2009
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
2006
Which glioblastoma multiforme patient will become a long-term survivor? A population-based study
1999
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma
2011
Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy
2001
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Enzymatic aminoacylation of tRNA with unnatural amino acids
2006 StandoutNobel
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
2004
Anti‐tumour efficacy on glioma models of PHA ‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrier
2013
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
2002
MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.
2001
Lessons learned in the development of targeted therapy for malignant gliomas
2007
Human DNA Repair Genes
2001 StandoutScienceNobel
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma
2002
hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
1999 StandoutNobel
Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
2003
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
2008
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors [RETIRED]
2000
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
2005
How effective is BCNU in recurrent glioblastoma in the modern era?
2004
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
2009
Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma
2006
E3 ubiquitin ligase Mindbomb 1 facilitates nuclear delivery of adenovirus genomes
2020 StandoutNobel
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
2015
Absorption by water increases fluorescence image contrast of biological tissue in the shortwave infrared
2018 StandoutNobel
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
2003
Chemical Glycoproteomics
2016 StandoutNobel
Extracellular microRNAs in human circulation are associated with miRISC complexes that are accessible to anti-AGO2 antibody and can bind target mimic oligonucleotides
2020 StandoutNobel
Works of Michael D. Prados being referenced
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
2005
Nonsynonymous Coding Single-Nucleotide Polymorphisms Spanning the Genome in Relation to Glioblastoma Survival and Age at Diagnosis
2007
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
2011
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
2009 Standout
Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma
2007
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
2007
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
2010
Phase 2 study of BCNU and temozolomide for recurrent glioblastomamultiforme: North American Brain Tumor Consortium study
2004
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme
1998
External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2 gliomas: NCOG study 6H-82-2
1991
Radiation Therapy and Hydroxyurea Followed by the Combination of 6-Thioguanine and BCNU for the Treatment of Primary Malignant Brain Tumors
1998
Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma
2003
Anaplastic Oligodendrogliomas: Prognostic Factors for Tumor Recurrence and Survival
2003
Permanent iodine 125 brachytherapy in patients with progressive orrecurrent glioblastoma multiforme
2004
A phase II study of temozolomide in patients with newly diagnosedsupratentorial malignant glioma before radiation therapy
2002
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1
2006
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plustemozolomide: A North American Brain Tumor Consortium study
2000
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
2008
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
2004
Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant β-interferon and hyperfractionated radiation therapy: A Childrens Cancer Group phase I/II study
1996
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
2006
Response and progression in recurrent malignant glioma
1999
Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13—PE38QQR for recurrent malignant glioma
2005
Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma
1998
Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma
2002
Interstitial irradiation and hyperthermia for the treatment of recurrent malignant brain tumors
1991
Necrosis as a prognostic factor in glioblastoma multiforme
1996
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost
1994
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
2004
Proliferative potential and prognostic evaluation of low-grade astrocytomas
1994
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignantglioma: A North American Brain Tumor Consortium study
2004
Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: The UCSF experience
1992
Long-Term Follow-Up after High-Activity <sup>125</sup>I Brachytherapy for Pediatric Brain Tumors
1996
Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood.
1993
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 incombination with carboplatin administered intravenously for the treatment ofrecurrent malignant glioma
2003
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404
2004
O 6-Benzylguanine suppression ofO6-alkylguanine-DNA alkyltransferase in anaplasticgliomas
2004
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
2005
Intravenous Carboplatin for Recurrent Gliomas
1996
Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy
1997
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen
1997
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
1992
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
2010
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
2008
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1
2006
Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study.
1991
Highly anaplastic astrocytoma: A review of 357 patients treated between 1977 and 1989
1992
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
2015
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme
2001
Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: Presentation of a detailed case study
1997
EGFR overexpression and radiation response in glioblastoma multiforme
2001
Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib
2005
Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors
1989
Radiation response and survival time in patients with glioblastoma multiforme
1996
A phase II study of intravenous carboplatin for the treatment of recurrent gliomas
1994
Recombinant interferon beta: a phase I-II trial in children with recurrent brain tumors.
1991
Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme
1996
Prognostic factors for survival of patients with glioblastoma: Recursivepartitioning analysis
2004
Targeting Wee1 for the treatment of pediatric high-grade gliomas
2013
A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants
2001
Meningiomas
1992
Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
2007
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients
2014
Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma
2007
Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors
2005
Temozolomide in the treatment of recurrent malignant glioma
2004
Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.
1998
The therapy of primary brain lymphoma
1991
Effect of disease burden on health-related quality of life in patientswith malignant gliomas
2000
Chemotherapy of brain tumors
1998
Evaluation of bromodeoxyuridine in glioblastoma multiforme: A A Northern California cancer center phase II study
1991
Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
2008
Chemotherapy for gliomas
1995
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide
2000
Final results of phase I/II studies of IL13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma
2005
Interstitial Irradiation and Hyperthermia for the Treatment of Recurrent Malignant Brain Tumors
1991
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
1999
Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.
2005
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: A North American Brain Tumor Consortium Study
2002
Phase II Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Either Receiving or Not Receiving Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
2006
Phase I Trial of Tipifarnib in Patients With Recurrent Malignant Glioma Taking Enzyme-Inducing Antiepileptic Drugs: A North American Brain Tumor Consortium Study
2005
Procarbazine, Lomustine, and Vincristine (PCV) Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine or PCV Adjuvant Chemotherapy
1999
A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).
2013
Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors.
1987
Future directions in the treatment of malignant gliomas with temozolomide.
2000
Biology and treatment of malignant glioma.
2000
Erlotinib HCL for glioblastoma multiforme in first relapse, a phase II trial
2004
A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs
2004
A phase II trial of thymidine and carboplatin for recurrent malignantglioma: A North American Brain Tumor Consortium Study
2002
Challenges in the design and conduct of phase III brain tumor therapy trials
1997
Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
2001
Phase II Evaluation of Temozolomide and 13-cis-Retinoic Acid for the Treatment of Recurrent and Progressive Malignant Glioma: A North American Brain Tumor Consortium Study
2003
Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.
1996
Survival and Functional Status after Resection of Recurrent Glioblastoma Multiforme
1998
Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium
2004
NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas
2004
Phase II Study of Fenretinide (NSC 374551) in Adults With Recurrent Malignant Gliomas: A North American Brain Tumor Consortium Study
2004
Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors
1997
Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole.
1992
A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM)
2008
Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery.
2001
Benefit of Temozolomide Compared to Procarbazine in Treatment of Glioblastoma Multiforme at First Relapse: Effect on Neurological Functioning, Performance Status, and Health Related Quality of Life
2005
Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601
2008
Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group
2007
Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma.
2002
Health-Related Quality of Life in Patients Treated With Temozolomide Versus Procarbazine for Recurrent Glioblastoma Multiforme
2000
Treatment of Progressive or Recurrent Glioblastoma Multiforme in Adults with Herpes Simplex Virus Thymidine Kinase Gene Vector-Producer Cells Followed by Intravenous Ganciclovir Administration: A Phase I/II Multi-Institutional Trial
2003
Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas
2008
18-fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma
1997
Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS)
2008
Long-Term Survival in Patients with Glioblastoma Multiforme
1993
A phase II study of XL184 in patients (pts) with progressive glioblastoma multiforme (GBM) in first or second relapse
2009
Age and Radiation Response in Glioblastoma Multiforme
2001
High activity iodine-125 interstitial implant for gliomas
1992
Large Effect of Age on the Survival of Patients with Glioblastoma Treated with Radiotherapy and Brachytherapy Boost
1995
Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study
2010
Gene expression and angiotropism in primary CNS lymphoma
2006
Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma Survival
2006
Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome
2005
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
1999
Effect of disease burden on health-related quality of life in patients with malignant gliomas
2000
Prognostic Associations of Activated Mitogen-Activated Protein Kinase and Akt Pathways in Glioblastoma
2006
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme
1996
Phase I Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results
2003
A Preliminary Study of the Prognostic Value of Proton Magnetic Resonance Spectroscopic Imaging in Gamma Knife Radiosurgery of Recurrent Malignant Gliomas
2000
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs
2004